Alatrofloxacin

From Self-sufficiency
Jump to: navigation, search
Alatrofloxacin
250px
Systematic (IUPAC) name
7-[(1R,5S)-6-{[(2S)-1-{[(2S)-
2-aminopropanoyl]amino}-1-oxopropan-2-yl]amino}-
3-azabicyclo[3.1.0]hexan-3-yl]-1-(2,4-difluorophenyl)-
6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acid
Clinical data
Pregnancy
category
  • US: C (Risk not ruled out)
Routes of
administration
Intravenous
Legal status
Legal status
  • Withdrawn
Pharmacokinetic data
Bioavailability N/A
Protein binding 76% (trovafloxacin)
Metabolism Quickly hydrolyzed to trovafloxacin
Biological half-life 9 to 12 hours (trovafloxacin)
Excretion Fecal and renal (trovafloxacin)
Identifiers
CAS Number 157182-32-6 157605-25-9 (mesylate)
ATC code none
PubChem CID 5489474
ChemSpider 2343243
Chemical data
Formula C26H25F3N6O5
Molar mass 558.509 g/mol[[Script error: No such module "String".]]
Script error: No such module "collapsible list".
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Alatrofloxacin (Trovan IV) is a fluoroquinolone antibiotic developed by Pfizer, delivered as a mesylate salt.[1] It is the parental prodrug of trovafloxacin (Trovan) meant for intravenous administration. Trovafloxacin is a broad-spectrum antibiotic introduced in 1998 which encountered criticism for its Nigerian trials and adverse clinical reactions.[2][3]

Trovafloxacin and alatrofloxacin were both withdrawn from the U.S. market in 2001.

See also

References

  1. "PubChem CID 5489474". 
  2. Hall IH, Schwab UE, Ward ES, Ives TJ (2003). "Effects of alatrofloxacin, the parental prodrug of trovafloxacin, on phagocytic, anti-inflammatory and immunomodulation events of human THP-1 monocytes". Biomed. Pharmacother. 57 (8): 359–65. doi:10.1016/S0753-3322(03)00054-4. PMID 14568230. 
  3. Lenzer J (2006). "Secret report surfaces showing that Pfizer was at fault in Nigerian drug tests". BMJ. 332 (7552): 1233. doi:10.1136/bmj.332.7552.1233-a. PMC 1471980Freely accessible. PMID 16735322. 
it:Alatrofloxacina